Compare TCPC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCPC | REPL |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.1M | 407.1M |
| IPO Year | 2006 | 2018 |
| Metric | TCPC | REPL |
|---|---|---|
| Price | $3.87 | $8.60 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 9 |
| Target Price | $3.50 | ★ $5.67 |
| AVG Volume (30 Days) | 667.2K | ★ 6.0M |
| Earning Date | 05-07-2026 | 05-21-2026 |
| Dividend Yield | ★ 18.23% | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.43 | $1.50 |
| 52 Week High | $8.05 | $13.24 |
| Indicator | TCPC | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 76.20 |
| Support Level | $3.43 | $8.24 |
| Resistance Level | $4.46 | $9.01 |
| Average True Range (ATR) | 0.13 | 0.65 |
| MACD | -0.04 | 0.34 |
| Stochastic Oscillator | 28.89 | 95.38 |
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.